A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer - Wikidata - awgldk - TriplyDB

A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer

A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer

http://www.wikidata.org/entity/Q34978404

about

Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.

P2860

Q38812867-E0ED455D-8C11-4771-9F90-AD871B8E486A

P2860

A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer

http://www.wikidata.org/entity/Q34978404

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A phase I trial of combination ...... patients with advanced cancer

@ast

A phase I trial of combination ...... patients with advanced cancer

@en

A phase I trial of combination ...... patients with advanced cancer

@nl

type

label

A phase I trial of combination ...... patients with advanced cancer

@ast

A phase I trial of combination ...... patients with advanced cancer

@en

A phase I trial of combination ...... patients with advanced cancer

@nl

prefLabel

A phase I trial of combination ...... patients with advanced cancer

@ast

A phase I trial of combination ...... patients with advanced cancer

@en

A phase I trial of combination ...... patients with advanced cancer

@nl

P1433

Q34978404-5A13B276-5C84-42D2-9A2A-AE838C9761F8

P1476

Q34978404-07AC7E90-3233-4EFC-A60A-E3D35B535394

P2093

Q34978404-00326B83-D2FA-4CA3-BA99-C4B8760E494F

Q34978404-320A7A71-5B9A-47F0-8969-EAB11DBA6E8B

Q34978404-37CBF9AE-9934-4A62-BB3C-98619F7DC68C

Q34978404-48311E59-1F1A-45F1-9341-40F208E295E6

Q34978404-6399F6A1-708B-41A2-9DF7-FA2BFD9D2A69

Q34978404-6D01EE79-AA4E-4714-B608-8996E0C9E011

Q34978404-78DE34CF-A451-4E7A-A7A7-F71A33CCC5EF

Q34978404-7CF885FF-DC3B-4DC2-AD61-CA5F55CF5E66

Q34978404-9EBBAF13-30A0-490E-A5AA-0FEE1C57E326

Q34978404-EF046A6B-A755-4BDD-88FB-2CA3FA7F3F07

P2860

Q34978404-0025B92C-8D10-4131-9B91-5B64875A7949

Q34978404-036270EF-A1D1-4A71-80F2-536CE14081C0

Q34978404-0671C286-BE84-4341-87F6-340AF6B4F2FB

Q34978404-0ADF6CF6-C807-4E3B-8341-30D2B6E489A7

Q34978404-0D05971C-A885-47FF-AEE2-251BFBBDF231

Q34978404-0D7D3FF3-62FB-4DBB-B970-7E894A965BBC

Q34978404-1295C23E-F911-4AAF-AFA0-7A127A432662

Q34978404-26B0ACE8-1A0C-4B7E-B43F-17BFB0FBF9C7

Q34978404-28F67972-1A7B-4682-A8C3-D9156B3EF42F

Q34978404-2A1A837B-5D2E-41F0-A964-8BA9B84AC329

P2888

Q34978404-969D4918-4891-4AE2-AB27-BB6F5B9F2BBB

P304

Q34978404-5086EB4C-CA94-4F23-A2C9-26DD7660A091

P31

Q34978404-099DA5B1-8E75-4E4A-989B-A2015B1FCBF0

P356

Q34978404-5D8EBB3E-2F81-442D-B265-F546814A8350

P433

Q34978404-35EC2F4C-6F5A-4E3F-99DB-DFAA626ED8DD

P478

Q34978404-142B50E5-55EC-47B1-90B8-B973BD4CAB58

P50

Q34978404-3625D318-A409-4BC0-BD2D-DD973F212F38

Q34978404-3AF1499E-F473-439E-ABA3-97F626BB270B

Q34978404-7257ECB4-0B6A-403D-9F6B-0FE6E02B5313

Q34978404-89B7EB69-687B-4B23-8AE2-1C409582FA79

P577

Q34978404-46581D84-D543-4F71-9ABB-EB6F7FE73A61

P6179

Q34978404-2AA7AFCB-9DFE-4D1A-A1BF-9490D5886C9D

P698

Q34978404-BC9402B7-6A55-4DA7-B56A-09613E575E6E

P921

Q34978404-AB59956C-EBB0-409D-95EA-A9F7558DF260

Q34978404-D32B51E3-0E3F-4BD1-98AB-3251F9404D1F

P932

Q34978404-7935A4A9-B9C0-4EF1-98B4-979F27154483

P356

S10637-014-0173-7

P1433

Investigational New Drugs

P1476

A phase I trial of combination ...... patients with advanced cancer

@en

P2093

David S Hong

http://www.w3.org/2001/XMLSchema#string

Gerald S Falchook

http://www.w3.org/2001/XMLSchema#string

Jennifer J Wheler

http://www.w3.org/2001/XMLSchema#string

Kristin L Parkhurst

http://www.w3.org/2001/XMLSchema#string

Mei Huang

http://www.w3.org/2001/XMLSchema#string

Ralph Zinner

http://www.w3.org/2001/XMLSchema#string

Sarina A Piha-Paul

http://www.w3.org/2001/XMLSchema#string

Siqing Fu

http://www.w3.org/2001/XMLSchema#string

Stacy Moulder

http://www.w3.org/2001/XMLSchema#string

Yunfang Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Survival of cancer cells is maintained by EGFR independent of its kinase activity

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

P2888

s10637-014-0173-7

P304

177-186

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-014-0173-7

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Razelle Kurzrock

Apostolia Maria Tsimberidou

P577

2014-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1025993355

http://www.w3.org/2001/XMLSchema#string

P698

25323060

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4297242

http://www.w3.org/2001/XMLSchema#string